Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 576-581

  Sugarbaker, Paul H ^a   Bijelic, Lana ^a   Chang, David ^b   Yoo, Dal ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b WESTAT   (United States)

Author keywords

5 fluorouracil; cytoreductive surgery; intraperitoneal chemotherapy; neoadjuvant chemotherapy; oxaliplatin; peritonectomy; second look surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; APPENDIX CANCER; APPENDIX MUCINOUS ADENOCARCINOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; MALE; MUCINOUS CARCINOMA; PERITONEAL MUCINOUS CARCINOMATOSIS; PERITONEUM CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VAGINAL HYSTERECTOMY;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS;

EID: 78349257346     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21679     Document Type: Article

References (20)

1. Bristow RE, Chi DS:, Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006; 103: 1070-1076.
2. Kaklamanos IG, Walker GR, Ferry K, et al.: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754-761.
3. Urshcel JD, Vasan H:, A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
4. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
5. Merkel S, Mansmann U, Hohenberger W, et al.: Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment. A systematic review and meta-analysis. Colorectal Dis 2009; PMID: 19895596 [Epub ahead of print].
6. Ruo L, Tickoo S, Klimstra DS, et al.: Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 75-81.
7. Portera CC, Swain SM:, Neoadjuvant chemotherapy: A step closer to individualized therapy. ASCO 2007; 07: 51-55.
8. Sugarbaker PH, Ronnett BM, Archer A, et al.: Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30: 233-280.
9. Sugarbaker PH:, Appendiceal epithelial neoplasms and pseudomyxoma peritonei, a distinct clinical entity with distinct treatments. In:, Bland KI, Buchler MW, Csendes A, Garden OJ, Sarr MG, Wong J, editors. General surgery: Principles and international practice, 2nd edition. London: Springer-Verlag; 2009. pp. 885-893.
10. Ronnett BM, Zahn CM, Kurman RJ, et al.: Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei. " Am J Surg Pathol 1995; 19: 1390-1408.
11. Sugarbaker PH:, New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome ? Lancet Oncol 2006; 7: 69-76.
12. Elias D, Gilly F, Quenet F, et al.: Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010; 36: 456-462.
13. Sugarbaker PH:, Epithelial appendiceal neoplasms. Cancer J 2009; 15: 225-235.
14. Sanoff HK, Sargent DJ, Campbell ME, et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-5727.
15. Capussotti L, Muratore A, Mulas MM, et al.: Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 2006; 93: 1001-1006. (Pubitemid 44214852)
16. de Gramont A, Vignoud J, Tournigand C, et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-219.
17. Cohen J:, A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
18. Yan H, Pestieau SR, Shmookler BM, et al.: Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: Failure vs. success with a second-look operation. Mod Pathol 2001; 14: 164-171.
19. Jacquet P, Jelinek JS, Steves MA, et al.: Evaluation of computer tomography in patients with peritoneal carcinomatosis. Cancer 1993; 72: 1631-1636.
20. da Silva RG, Sugarbaker PH:, Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203: 878-886.